New partnership with GoodRx to lower costs for uninsured and underinsured patients.
Transaction Includes U.S. and Canadian Commercial Rights to FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, ZERVIATE, and Non-Prescription Brands FRESHKOTE and Cationorm PLUS.
VEVYE is the first and only cyclosporine-based product indicated for the treatment of both signs and symptoms of dry eye disease with efficacy demonstrated after four...
This marks the second transaction between Harrow and Novartis.
Get the most important news and business ideas for eyecare professionals every weekday from INVISION.
Tons of business ideas for eyecare professionals!
Advertisement
